keyword
MENU ▼
Read by QxMD icon Read
search

Asthma immunotherapy

keyword
https://www.readbyqxmd.com/read/29656145/sq-house-dust-mite-sublingual-immunotherapy-tablet-subgroup-efficacy-and-local-application-site-reaction-duration
#1
David I Bernstein, Joerg Kleine-Tebbe, Harold S Nelson, Jose A Bardelas, Gordon L Sussman, Susan Lu, Dorte Rehm, Bodil Svanholm Fogh, Hendrik Nolte
BACKGROUND: Allergic rhinitis with or without conjunctivitis (AR/C) is common, necessitating evaluation of SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet efficacy in various subgroups. OBJECTIVE: To evaluate 12 SQ-HDM efficacy and safety across subgroups, and the onset, duration, and recurrence of local application site reactions. METHODS: Subgroup (age, gender, race, asthma status, and allergen sensitization) efficacy was assessed using pooled data from two previously described trials of daily 12 SQ-HDM vs placebo for AR/C (N=2138)...
April 12, 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29642713/house-dust-mite-sublingual-immunotherapy-for-pediatric-patients-with-allergic-asthma
#2
Jessika R Richards, Janice L Stumpf
OBJECTIVE: To review the published literature evaluating administration of house dust mite (HDM) sublingual immunotherapy (SLIT) in pediatric patients with allergic asthma. DATA SOURCES: PubMed database search (1966 to November 2017) using the search terms allergy, allergic rhinitis, asthma, allergic asthma, house dust mite, allergen immunotherapy, subcutaneous immunotherapy, sublingual immunotherapy, MK-8237, children, and pediatric. Package labeling and references from identified articles were also reviewed...
April 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29629956/what-you-should-not-miss-from-the-systematic-reviews-and-meta-analyses-on-allergen-specific-immunotherapy-in-2017
#3
Désirée Larenas-Linnemann, Jorge A Luna-Pech
PURPOSE OF REVIEW: Allergen immunotherapy (AIT) is a well recognized and extensively studied therapeutic intervention for some allergic diseases. Every year new systematic reviews and meta-analysis provide the most powerful source of evidence to orient decision making on prevention or efficacy of AIT. We here discuss systematic reviews and meta-analyses on AIT (published January 2017 to February 2018). RECENT FINDINGS: We identified 4 systematic reviews and 10 meta-analyses...
April 6, 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29629055/accuracy-of-immunoblotting-assay-for-detection-of-specific-ige-compared-with-immunocap-in-allergic-patients
#4
Raheleh Shokouhi Shoormasti, Mohammad Reza Fazlollahi, Anoshirvan Kazemnejad, Masoud Movahedi, Behnoosh Tayebi, Zahra Yazdanyar, Zakieh Azadi, Zahra Pourpak, Mostafa Moin
Background and aim: Standardized techniques help us to better diagnosis and follow up of allergic diseases. In this study, we determined the sensitivity, accuracy, and specificity of an Immunoblotting test compared to ImmunoCAP as the reference in vitro test for detection of specific IgE in allergic patients. Methods: In this cross-sectional study, specific IgE level was determined in patients with allergic symptoms who referred to the Immunology, Asthma and Allergy Research Institute, Tehran, Iran from 2010-2016, by two techniques...
February 2018: Electronic Physician
https://www.readbyqxmd.com/read/29625665/subcutaneous-venom-immunotherapy-in-children-efficacy-and-safety
#5
Pınar Gür Çetinkaya, Saliha Esenboğa, Özge Uysal Soyer, Ayfer Tuncer, Bülent Enis Şekerel, Ümit Murat Şahiner
BACKGROUND: Venom immunotherapy (VIT) is safe in children, although adverse effects can occur. OBJECTIVE: To document adverse effects and to determine re-sting reactions and the efficacy of VIT in childhood. METHODS: We retrospectively analyzed data from children who had taken VIT from 2002 through 2015. These patients were queried by telephone to determine reactions after re-stings during or after VIT. RESULTS: In total 107 children with a systemic reaction after Hymenoptera sting and with proved immunoglobulin E-mediated sensitization were enrolled...
April 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29620296/-sublingual-immunotherapy-for-the-treatment-of-allergic-rhinoconjonctivitis-and-asthma-a-practical-approach
#6
Jacqueline Ghosn, François Spertini, Denis Comte
The prevalence of allergic diseases has been increasing over the past 50 years, leading to social and economic consequences. Immunotherapy is the only disease-modifying therapy available for allergic diseases, with durable long-term benefits. Immunotherapy is primarily available in two forms : 1) subcutaneous injections or 2) sublingual tablets/drops. The latter offers the advantage of being managed by the patient himself, requires no injections and has a far lower risk of severe systemic adverse events. In Switzerland, the use of sublingual immunotherapy is still scarce...
April 4, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29620295/-place-of-immunotherapy-in-allergic-asthma
#7
Ophélie Marchal, Daniele Allali
Desensitization for pneumallergens is used in daily practice for the treatment of allergic rhinitis and allergic asthma. However, specific immunotherapy has long been debated in the medical literature as a treatment for allergic asthma until the latest international recommendations for the management of asthma (GINA) reveal specific immunotherapy as a treatment in sensitized patients, poorly controlled by inhaled corticosteroids (FEV 1 > 70%). In this article you will find a current overview of the medical literature on the usefulness of specific desensitization to reduce asthma symptoms and symptomatic treatments, prevent the onset of asthma in patients with allergic rhinitis as well as prevent new sensitizations...
April 4, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29574666/impact-of-increasing-treatment-rates-on-cost-effectiveness-of-subcutaneous-immunotherapy-scit-in-respiratory-allergy-a-decision-analytic-modelling-approach
#8
Ann-Kathrin Richter, Ludger Klimek, Hans F Merk, Norbert Mülleneisen, Harald Renz, Wolfgang Wehrmann, Thomas Werfel, Eckard Hamelmann, Uwe Siebert, Gaby Sroczynski, Jürgen Wasem, Janine Biermann-Stallwitz
BACKGROUND: Specific immunotherapy is the only causal treatment in respiratory allergy. Due to high treatment cost and possible severe side effects subcutaneous immunotherapy (SCIT) is not indicated in all patients. Nevertheless, reported treatment rates seem to be low. This study aims to analyze the effects of increasing treatment rates of SCIT in respiratory allergy in terms of costs and quality-adjusted life years (QALYs). METHODS: A state-transition Markov model simulates the course of disease of patients with allergic rhinitis, allergic asthma and both diseases over 10 years including a symptom-free state and death...
March 24, 2018: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/29574527/treatment-of-allergic-rhinitis-as-a-strategy-for-preventing-asthma
#9
REVIEW
Jaymin B Morjaria, Massimo Caruso, Rosalia Emma, Cristina Russo, Riccardo Polosa
PURPOSE OF REVIEW: To evaluate the impact of allergic rhinitis (AR) on the development of asthma and to update readers on recent literature suggesting that early treatment of allergic subjects with immunotherapy may prevent asthma onset. RECENT FINDINGS: AR is frequently associated with asthma, leading to the concept that these two conditions are different aspects of the same disease. There is increasing evidence that AR precedes the onset of asthmatic symptoms and current treatment strategies are beneficial in symptom control with no impact prevention...
March 24, 2018: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/29572287/allergen-specific-immunotherapy-in-the-treatment-of-pediatric-asthma-a-systematic-review
#10
REVIEW
Jessica L Rice, Gregory B Diette, Catalina Suarez-Cuervo, Emily P Brigham, Sandra Y Lin, Murugappan Ramanathan, Karen A Robinson, Antoine Azar
CONTEXT: Treatment options for allergic asthma include allergen avoidance, pharmacotherapy, and allergen immunotherapy. OBJECTIVES: Summarize and update current evidence for the efficacy and safety of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) in pediatric allergic asthma. DATA SOURCES: PubMed, Embase, Cochrane Central Register of Controlled Trials (January 1, 2005, through May 8, 2017), ClinicalTrials.gov, and the US Food and Drug Administration Adverse Event Reporting System...
March 23, 2018: Pediatrics
https://www.readbyqxmd.com/read/29569506/impact-of-allergen-immunotherapy-in-allergic-asthma
#11
Wenming Zhang, Chunrong Lin, Vanitha Sampath, Kari Nadeau
Although traditional pharmacological approaches improve outcomes in disease management for allergic asthma, these fail to modify the underlying immune responses. Allergen immunotherapy remains the only etiological therapy for the treatment of respiratory allergies for which clinical efficacy has been demonstrated through several well-controlled studies. In this review, we examine evidence from the past 5 years regarding the impact of allergen immunotherapy on allergic asthma to inform practitioners and stimulate further discussion and research...
March 23, 2018: Immunotherapy
https://www.readbyqxmd.com/read/29562802/house-dust-mite-sublingual-immunotherapy-in-allergic-rhinitis
#12
Sung-Woo Cho, Doo Hee Han, Jeong-Whun Kim, Dong-Young Kim, Chae-Seo Rhee
Allergen immunotherapy has been shown to be effective in treatment of allergic rhinitis (AR). Sublingual immunotherapy (SLIT) is generally recommended for treating seasonal AR in adults and children; however, questions remain in regard to AR treatment in relation to house dust mite (HDM). Due to heterogeneous formulations, different outcome reporting systems, and the lack of a standardized dose, HDM SLITs have not been standardized in published studies. Nevertheless, studies continuously report positive effects of HDM SLIT in AR, and HDM SLIT remains a treatment option for patients with HDM-induced allergic asthma that frequently co-exists with AR...
March 22, 2018: Immunotherapy
https://www.readbyqxmd.com/read/29551533/immunotherapy-with-the-sq-tree-slit-tablet-in-adults-and-adolescents-with-allergic-rhinoconjunctivitis
#13
Mika J Mäkelä, Pär Gyllfors, Erkka Valovirta, Maria A Steffensen, Pernille M Grønager, Johannes Savolainen, Lone Winther
PURPOSE: The SQ tree sublingual immunotherapy (SLIT)-tablet containing allergen extracts with the major allergen Bet v 1 from birch pollen is currently being developed for the treatment of tree pollen-induced allergic rhinitis/conjunctivitis with or without asthma. The aim of this Phase II trial was to investigate the dose-related efficacy and safety of the SQ tree SLIT-tablet. METHODS: This study was a randomized, parallel-group, double-blind, placebo-controlled, multi-national trial conducted in Europe...
March 15, 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29551278/the-efficacy-of-sublingual-immunotherapy-for-allergic-diseases-in-asia
#14
REVIEW
Xuandao Liu, Chew Lip Ng, De Yun Wang
Sublingual immunotherapy (SLIT) has been proven to be safe and effective from an abundance of Western literature, but data from Asia is less complete. This review aims to examine the basic science, safety and efficacy of SLIT in Asian patients, and to determine future research needs in Asia. We performed a literature search on PUBMED, Scopus, and Cochrane Library database for articles on SLIT originating from Asian countries through Nov 2017. There were 18 randomized, double-blind, placebo-controlled trials, of which 9 involved solely paediatric subjects...
March 15, 2018: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/29527129/a-critical-appraisal-on-ait-in-childhood-asthma
#15
REVIEW
Matteo Ferrando, Francesca Racca, Lorena Nascimento Girardi Madeira, Enrico Heffler, Giovanni Passalacqua, Francesca Puggioni, Niccolò Stomeo, Giorgio Walter Canonica
Abstract: Allergen immunotherapy (AIT) is the only disease-modifying treatment approved for allergic rhinitis and allergic asthma and represents a suitable therapeutic option, especially in childhood, to modify the progression of respiratory allergic diseases. Starting from the previous "generic class effect" evaluation, as testified by the numerous meta analyses, AIT is now considered a product-specific pathogenic-oriented treatment. Background: AIT was empirically proposed more than one century ago in the subcutaneous form (SCIT), but the IgE-mediated mechanism of allergy was elucidated only after 50 years of clinical use of the treatment...
2018: Clinical and Molecular Allergy: CMA
https://www.readbyqxmd.com/read/29512827/short-course-of-grass-allergen-peptides-immunotherapy-over-three-weeks-reduces-seasonal-symptoms-in-allergic-rhinoconjunctivitis-with-without-asthma-a-randomized-multicenter-double-blind-placebo-controlled-trial
#16
Ralph Mösges, Claus Bachert, Petr Panzner, Moises A Calderon, Ludo Haazen, Sabine Pirotton, Nathalie Wathelet, Stephen R Durham, Marie-Alix Bonny, Thierry Legon, Remy von Frenckell, Oliver Pfaar, Mohamed H Shamji
BACKGROUND: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. METHODS: In a randomized, double blind, placebo-controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks...
March 7, 2018: Allergy
https://www.readbyqxmd.com/read/29498435/dental-follicle-mesenchymal-stem-cells-downregulate-th2-mediated-immune-response-in-asthmatic-patients-mononuclear-cells
#17
Deniz Genç, Noushin Zibandeh, Ercan Nain, Muazzez Gökalp, Ahmet Oğuzhan Özen, Mehmet Kamil Göker, Tunç Akkoç
BACKGROUND: Asthma is a chronic inflammatory disease in which inflammatory responses have the polarization of CD4+ T cells to Th2 cells. Dental follicle mesenchymal stem cells (DFSCs) have strong anti-inflammatory properties comparable to other mesenchymal stem cells. OBJECTIVE: We investigated the immunomodulatory effects of DFSCs on CD4+ T helper cell responses of asthmatic patients and compared the results with those obtained with asthmatic subjects on immunotherapy and with healthy individuals...
March 2, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29461859/epidemic-thunderstorm-asthma-protection-with-five-grass-pollen-tablet-sublingual-immunotherapy
#18
Robyn E O'Hehir, Nirupama P Varese, Kirsten Deckert, Celia M Zubrinich, Menno C van Zelm, Jennifer M Rolland, Mark Hew
No abstract text is available yet for this article.
February 20, 2018: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29446469/clinical-trials-in-allergen-immunotherapy-current-concepts-and-future-needs
#19
REVIEW
O Pfaar, M Alvaro, V Cardona, E Hamelmann, R Mösges, J Kleine-Tebbe
Allergen immunotherapy (AIT) is a safe, effective treatment for allergic rhinoconjunctivitis and allergic asthma. However, AIT's clinical effect is still contested - primarily due to heterogeneity in clinical trial designs, study populations, therapeutic formulations and efficacy criteria. After discussing current concepts and unmet needs, an international panel of experts made several recommendations: (i) explore and validate definitions for [clinical] responders in AIT-trials; (ii) use of well-documented, standardized provocation tests prior to inclusion of subjects with relevant diseases in AIT trials; (iii) monitoring neo-sensitizations and occurrence of new allergy in extended AIT trials, and exclusion of polyallergic participants; (iv) validation of allergen exposure chambers with regard to natural exposure; (v) in studies of seasonal allergies, focus on peak exposure but also consider organising two parallel, geographically distinct but otherwise identical trials; (vi) discuss adaptive trial designs with the regulatory authorities; (vii) use e-health and m-health technologies to capture more information on individual exposure to allergens; (viii) initiate research on potential psychological, biochemical, immune, neural and even genomic markers of the placebo response; (ix) identify trial designs and primary endpoints that will give children with allergies easier, faster access to AIT formulations; and (x) promote and apply standardized methods for reporting systemic and local adverse events...
February 15, 2018: Allergy
https://www.readbyqxmd.com/read/29434524/the-control-of-allergic-rhinitis-in-real-life-a-multicenter-cross-sectional-italian-study
#20
Federica Gani, Carlo Lombardi, Laura Barrocu, Massimo Landi, Erminia Ridolo, Massimo Bugiani, Giovanni Rolla, Gianenrico Senna, Giovanni Passalacqua
Background: Allergic Rhinitis (AR) is a high-prevalence disease. In Europe about 25% of the general population is affected, and in Italy the prevalence is estimated to be 19.8%. The Allergic Rhinitis and its Impact on Asthma (ARIA) international document underlined that the prevalence of severe or refractory or overlapping rhinitis is increasing and represents a non-negligible socio-economic burden. In general, despite the social healthcare costs, allergic rhinitis remains underestimated, not sufficiently controlled and often undertreated...
2018: Clinical and Molecular Allergy: CMA
keyword
keyword
15390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"